Division of Surgical Oncology, Department of Surgery, Johns Hopkins University, Baltimore, MD, USA.
Division of Surgical Oncology, Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
J Gastrointest Surg. 2021 Nov;25(11):2908-2919. doi: 10.1007/s11605-021-04953-y. Epub 2021 Feb 25.
Prognostication based on preoperative clinical factors is lacking in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). This study aims to determine the value of preoperative tumor markers as predictors of progression-free survival (PFS) and overall survival (OS) for patients with peritoneal carcinomatosis from a primary mucinous adenocarcinoma of the appendix (MACA).
We queried the United States HIPEC Collaborative, a database of patients with peritoneal carcinomatosis treated with CRS/HIPEC at twelve institutions between 2000 and 2017, identifying 409 patients with MACA. Multivariate analysis was used to identify independent predictors of disease progression. Subgroup analysis was conducted to evaluate the impact of tumor grade on the predictive value of tumor markers.
CA19-9 [HR 2.44, CI 1.2-3.4] emerged as an independent predictor of PFS while CEA [HR 4.98, CI 1.06-23.46] was independently predictive of OS (p <0.01). Tumor differentiation was the most potent predictor of both PFS (poorly differentiated vs well, [HR 4.5 CI 2.01-9.94]) and OS ([poorly differentiated vs well-differentiated: [HR 13.5, CI 3.16-57.78]), p <0.05. Among patients with combined CA19-9 elevation and poorly differentiated histology, 86% recurred within a year of CRS/HIPEC (p < 0.01). Similarly, the coexistence of CEA elevation and unfavorable histology led to the lowest survival rate at two years [36%, p < 0.01]. CA-125 was not predictive of PFS or OS.
Elevated preoperative CA19-9 portends worse PFS, while elevated CEA predicts worse OS after CRS/HIPEC in patients with MACA. This study provides additional evidence that CA19-9 and CEA levels should be collected during standard preoperative bloodwork, while CA-125 can likely be omitted. Tumor differentiation, when added to preoperative tumor marker levels, provides powerful prognostic information. Prospective studies are required to confirm this association.
在接受细胞减灭术和腹腔热灌注化疗(CRS/HIPEC)的患者中,基于术前临床因素的预后预测仍然缺乏。本研究旨在确定术前肿瘤标志物作为预测原发性阑尾粘液腺癌(MACA)患者腹膜转移患者无进展生存期(PFS)和总生存期(OS)的价值。
我们查询了美国 HIPEC 协作组,这是一个在 2000 年至 2017 年间在 12 个机构接受 CRS/HIPEC 治疗的腹膜转移患者数据库,共确定了 409 例 MACA 患者。采用多变量分析确定疾病进展的独立预测因素。进行亚组分析以评估肿瘤分级对肿瘤标志物预测价值的影响。
CA19-9[HR 2.44,CI 1.2-3.4]是 PFS 的独立预测因子,而 CEA[HR 4.98,CI 1.06-23.46]是 OS 的独立预测因子(p<0.01)。肿瘤分化是预测 PFS(低分化与高分化,[HR 4.5 CI 2.01-9.94])和 OS([低分化与高分化:[HR 13.5,CI 3.16-57.78])的最有力预测因子,差异均具有统计学意义(p<0.05)。在 CA19-9 升高和组织学低分化的患者中,86%的患者在 CRS/HIPEC 治疗后一年内复发(p<0.01)。同样,CEA 升高和不良组织学共存导致两年后生存率最低[36%,p<0.01]。CA-125 对 PFS 或 OS 均无预测价值。
术前 CA19-9 升高预示着 PFS 更差,而 CEA 升高则预示着 MACA 患者接受 CRS/HIPEC 后 OS 更差。本研究进一步证实,CA19-9 和 CEA 水平应在标准术前血液检查中收集,而 CA-125 可能可以忽略不计。肿瘤分化,当与术前肿瘤标志物水平相结合时,提供了强大的预后信息。需要前瞻性研究来证实这种关联。